Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
NCT05405894
·
clinicaltrials.gov ↗
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Osteoporosis
Osteoporosis, Postmenopausal
Osteopenia
Bone Loss
Interventions
DRUG:
Zoledronic acid
Sponsor
University of Calgary